Rick Gonzalez

AbbVie talks next steps as first Humira competitor makes it to market
AbbVie talks next steps as first Humira competitor makes it to market
Endpoints
AbbVie
Humira
biosimilars
Rick Gonzalez
Flag link:
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
AbbVie
earnings
Rick Gonzalez
Skyrizi
Rinvoq
Flag link:
Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label
Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label
Fierce Pharma
AbbVie
Pharma CEOs
Rick Gonzalez
Rinvoq
FDA
Flag link:
Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Check?
Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Check?
Yahoo/Simply Wall St
Pharma CEOs
AbbVie
Rick Gonzalez
executive pay
Flag link:
Forget Humira -- Here's What You Need to Know About AbbVie
Forget Humira -- Here's What You Need to Know About AbbVie
Motley Fool
AbbVie
Humira
Upadacitinib
risankizumab
Rick Gonzalez
Flag link:
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
Endpoints
AbbVie
Humira
Rick Gonzalez
Flag link:
AbbVie CEO: Unlikely to Pursue Another $50 Billion Deal
AbbVie CEO: Unlikely to Pursue Another $50 Billion Deal
WSJ Online
AbbVie
M&A
Rick Gonzalez
Flag link:
AbbVie CEO Says Humira Will Blunt $1B Hit To Lipid Franchise
AbbVie CEO Says Humira Will Blunt $1B Hit To Lipid Franchise
Forbes
Rick Gonzalez
Humira
AbbVie
Flag link: